Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma

Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improveme...

Celý popis

Podrobná bibliografia

Vydané v:	Cancer research communications Ročník 4; číslo 1; s. 18 - 27
Hlavní autori:	Badhai, Jitendra, Landman, Nick, Pandey, Gaurav Kumar, Song, Ji-Ying, Hulsman, Danielle, Krijgsman, Oscar, Chandrasekaran, Gayathri, Berns, Anton, van Lohuizen, Maarten
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States American Association for Cancer Research 03.01.2024
Predmet:	Animals Biomarkers Enhancer of Zeste Homolog 2 Protein - genetics Humans Lung Cancer Lung Neoplasms - drug therapy Melanoma - drug therapy Mesothelioma - drug therapy Mesothelioma, Malignant Mice Preclinical Models Small Molecule Agents Translational Research Tumor Suppressor Proteins - genetics Ubiquitin Thiolesterase - genetics
ISSN:	2767-9764, 2767-9764
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!